Advertisement

Physiological Principles for the Design of Hepatic Contrast Agents

  • D. D. Stark
Conference paper

Abstract

The general requirements for design of a clinically useful contrast agent for magnetic resonance imaging (MRI) are: (a) magnetic activity which alters image signal intensity; (b) biodistribution to normal tissue and exclusion by diseased tissue (or the reverse); and (c) low toxicity or a high margin of safety for the effective dose.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Engelstad BL, Wolf GL (1988) Contrast agents. In: Stark DD, Bradley WG (eds) Magnetic resonance imaging. Mosby, St. Louis, pp 161–181Google Scholar
  2. 2.
    Bean CP, Livingston D (1959) Superparamagnetism. J Appl Physiol 30:120S-129SCrossRefGoogle Scholar
  3. 3.
    Cullity BD (1976) Introduction to magnetic materials. Addison-Wesley, ReadingGoogle Scholar
  4. 4.
    Saini S, Frankel RB, Stark DD, Ferrucci JT (1988) Magnetism: a primer and review. Am J Roentgenol 150:735–743Google Scholar
  5. 5.
    Mendonca-Dias MH, Lauterbur PC (1986) Ferromagnetic particles as contrast agents for magnetic resonance imaging of the liver and spleen. Magn Reson Med 3:328–330PubMedCrossRefGoogle Scholar
  6. 6.
    Renshaw PF, Owens CS, MacLaughlin AC, Frey TG, Leigh JS (1986) Ferromagnetic contrast agents: a new approach. Magn Reson Med 3:217–255PubMedCrossRefGoogle Scholar
  7. 7.
    Gillis P, Koenig SH (1987) Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes and magnetite. Magn Res Med 5:323–345CrossRefGoogle Scholar
  8. 8.
    Bacon BR, Stark DD, Park CH et al. (1987) Ferrite particles, a new MRI contrast agent: lack of acute or chronic hepatotoxicity following intravenous administration. J Lab Clin Med 110:164–171PubMedGoogle Scholar
  9. 9.
    Stark DD, Weissleder R, Elizondo G et al. (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168:287–301Google Scholar
  10. 10.
    Wolf GL, Fobben ES (1984) Tissue proton T1 and T2 response to gadolinium-DTPA injection in rabbits: a potential contrast agent for MR imaging. Invest Radiol 19:324–328PubMedCrossRefGoogle Scholar
  11. 11.
    Bousquet JC, Saini S, Stark DD et al. (1988) Gadolinium-DOTA: characterization of new paramagnetic complex. Radiology 166:693–698PubMedGoogle Scholar
  12. 12.
    Stark DD (1988) The liver. In: Stark DD, Bradley WJ Jr (eds) Magnetic resonance imaging. Mosby, St. Louis, pp 934–1059Google Scholar
  13. 13.
    Greif WL, Buxton RB, Lauffer RB et al. (1985) Pulse sequence optimization for MR imaging using a paramagnetic hepatobiliary contrast agent. Radiology 157:461–466PubMedGoogle Scholar
  14. 14.
    Saini S, Stark DD, Wittenberg J et al. (1986) Dynamic gadolinium-DTPA imaging of liver cancer: animal investigation. Am J Roentgenol 147:357–362Google Scholar
  15. 15.
    Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD (1988) The effects of iron oxides on proton relaxivity. Magn Reson Imaging 6:647–653PubMedCrossRefGoogle Scholar
  16. 16.
    Hardy PA, Henkelman RM (1991) On the transverse relaxation rate enhancement induced by diffusion of spins through inhomogeneous fields. Magn Reson Med 17:348–356PubMedCrossRefGoogle Scholar
  17. 17.
    Haacke EM, Tkach JA, Parrish TB (1989) Reducing T2* dephasing in gradient field echo imaging. Radiology 170:457–462PubMedGoogle Scholar
  18. 18.
    Majumdar S, Zoghbi S, Pope CF, Gore JC (1989) A quantitative study of relaxation rate enhancement produced by iron oxide particles in polyacrylamide gels and tissue. Magn Reson Med 9:185–202PubMedCrossRefGoogle Scholar
  19. 19.
    Fisel CR, Ackerman JL, Buxton RB et al. (1991) MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med 17:336–347PubMedCrossRefGoogle Scholar
  20. 20.
    Fretz C J, Elizondo G, Weissleder R, Hahn PF, Stark DD, Ferrucci JT (1989) Superparamagnetic iron oxide-enhanced MR imaging: pulse sequence optimization for detection of liver cancer. Radiology 172:393–397PubMedGoogle Scholar
  21. 21.
    Fretz CJ, Stark DD, Metz CE et al. (1990) Detection of hepatic metastases: comparison of contrast enhanced CT, unenhanced MR imaging, and iron oxide enhanced MR imaging. Am J Roentgenol 155:763–770Google Scholar
  22. 22.
    Caride VJ, Sostman HD, Winchell RH, Gore JC (1984) Relaxation enhancement using liposomes carrying paramagnetic species. Magn Reson Imaging 2:107–112PubMedCrossRefGoogle Scholar
  23. 23.
    Fahlvik AK, Holtz E, Schroder U, Klaviness J (1990) Magnetic starch microspheres, biodistribution and biotransformation. Invest Radiol 25:793–797PubMedCrossRefGoogle Scholar
  24. 24.
    Lauffer RB, Greif WL, Stark DD et al. (1985) Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies. J Comput Assist Tomogr 9/3:431–438PubMedCrossRefGoogle Scholar
  25. 25.
    Elizondo G, Fretz C, Stark DD, Musu C, Ferrucci J (1989) GdBOPTA: preclinical efficacy evaluation as an hepatobiliary contrast agent for MR imaging. Radiology 173(P):253Google Scholar
  26. 26.
    Elizondo G, Fretz CJ, Stark DD, Rocklage SM, Quay SC, Worah D, Tsang TM, Chen MC, Ferrucci J (1991) Preclinical evaluation of Mn DPDP: new paramagnetic hepatobiliary agent for MR imaging. Radiology 178:73–78PubMedGoogle Scholar
  27. 27.
    Lim KO, Stark DD, Leese PT, Pfefferbaum A, Rocklage SM, Quay SC, Worah D (1991) Hepatobiliary MR imaging: first human experience with Mn-DPDP. Radiology 178:79–82PubMedGoogle Scholar
  28. 28.
    Vera DR, Krohn KA, Stadalnick RC, Scheibe PO (1984) 99mTc-galactosyl-neoglycoalbumin: in-vivo characterization of receptor-mediated binding to hepatocytes. Radiology 151:191–196PubMedGoogle Scholar
  29. 29.
    Wu GY, Midford S, Wu CH (1988) A hepatocyte directed contrast agent for magnetic resonance imaging of hepatic tumors. Hepatology 8:1253Google Scholar
  30. 30.
    Josephson L, Groman EV, Menz E, Lewis JM, Bengele H (1990) A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent. Magn Reson Imag 8:637–646CrossRefGoogle Scholar
  31. 31.
    Tanimoto A, Baba Y, Zhao L, Chen J, Pouliquen D, Stark DD (1991) Assessment of hepatitis with MR imaging: performance of cell-specific contrast agents. J Magn Reson Imaging 1:211Google Scholar
  32. 32.
    Tsang YM, Stark DD, Chen MC, Weissleder R, Wittenberg J, Ferrucci JT (1988) Hepatic micrometastases in the rat: ferrite enhancement MR imaging. Radiology 167:21–24PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • D. D. Stark

There are no affiliations available

Personalised recommendations